As Superpunch informs, popular and controversial predictions market platform Kalshi (previously) is expanding its betting profile from economic indicators, political and legislative outcomes and armed conflict to now include sports-like wagering in biotechnology, gambling on clinical trials and regulatory approval of new drug therapies. Already a highly speculative market subject to wild swings, opening up new contracts with Big Pharma, companies like Gilead, is expected to motivate traders to put their thumb on the scale, out of self-interest to improve their odds, with assuredly unscientific and deadly consequences. Kalshi, for its part defends its ethical stance, arguing, without scholarly consensus since the pool numbers are never disclosed, that the wisdom of the crowds and their investment on being right (or at least less wrong than the competition) more efficiently and accurately—a counterbalance to the greed, fraud and corruption endemic to the industry—steers optimal outcomes.
synchronoptica
one year ago: historic images of NASA’s research campus (with synchronoptica), assorted links to revisit, the flags of Iran plus new additions to UNESCO’s world heritage register
two years ago: American’s AI-military complex plus an evil cocktail
three years ago: Trump investigated for falsifying business records
five years ago: your daily demon plus the island of Kรฅllandsรถ
six years ago: Operation Jade Helm, unpopular essays plus more corporate sing-alongs
seven years ago: Les Horrible Cernettes, Wiesbaden’s Deutsches Filmhaus plus Trump’s disdain for the press
